使用勃林格殷格翰的思力华需要注意什么？

It is a long-acting anticholinergic drug developed by Boehringer Ingelheim. It has a selective inhibitory effect on M3 receptors and is suitable for the maintenance treatment of chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema) and related dyspnea. It has the advantages of long maintenance of blood concentration and few side effects.

Boehringer Ingelheim is a global group company with a rich and diverse cultural and social background, and is one of the top 20 pharmaceutical companies in the world. In the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing, approximately 50,000 employees around the world work hard to demonstrate value through innovation every day. The Spiriva developed by it is a prescription drug, and treatment needs to be started under the guidance of a doctor with experience in treatment.

Boehringer Ingelheim Sliver’s precautions are as follows:

1. Use is prohibited if the patient is allergic to tiotropium bromide or olodaterol or any other component of this medicine, or is allergic to atropine or related substances, such as ipratropine or oxytropine.

2. Patients with asthma (Respimat should not be used to treat asthma), heart disease, epilepsy, hypertension, thyrotoxicosis, diabetes, aneurysm, diabetes, severe liver damage, kidney damage, planned surgery, prostate problems or difficulty urinating, narrow-angle glaucoma and other diseases should consult the relevant physician before taking the medication and use the medication with caution.

3. Avoid Slihua medicine getting into your eyes. If you accidentally get it, please rinse it with plenty of water immediately.

4. If serious adverse reactions occur during treatment with Silihua, you need to contact your doctor in time for treatment. Do not take medication blindly to avoid causing more serious harm to the body.

5. Pregnant and lactating women should use with caution. Not for use by patients under 18 years of age.

Recommended related hot articles: /newsDetail/88983.html